Crossbow Therapeutics is a clinical-stage biotechnology company engaged in the research and development of innovative antibody-based therapies for cancer. Crossbow is developing a broad portfolio of novel T-cell engager (TCE) therapies that potently target peptide human leukocyte antigen (pHLA) on cancer cells, using antibodies that mimic T-cell receptors (TCR-mimetics).